Skip to main content
. Author manuscript; available in PMC: 2017 Jul 19.
Published in final edited form as: Muscle Nerve. 2016 Dec 28;55(4):570–581. doi: 10.1002/mus.25370

FIGURE 3.

FIGURE 3

Phase contrast images of DRGs treated with growth factor combinations (starting from top left). (a) control (0 ng/ml). (b) NGF 1 ng/ml + FK506 1 ng/ml. (c) NGF 1 ng/ml + FK506 10 ng/ml. (d) GDNF 1 ng/ml + FK506 1 ng/ml. (e) GDNF 1 ng/ml + FK506 10 ng/ml. (f) NGF 1 ng/ml + GDNF 1 ng/ml + FK506 1 ng/ml. (g) NGF 1 ng/ml + GDNF 1 ng/ml + FK506 10 ng/ml. (h) NGF 10 ng/ml + GDNF 10 ng/ml + FK506 10 ng/ml. (i) NGF 1 ng/ml + GDNF 1 ng/ml. Neurite outgrowth is increased with combined treatment of FK506 with growth factors. Scale = 500 μm.